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Abstract
Objective—ABT-751, a novel orally available antitubulin agent, is mainly eliminated as inactive
glucuronide (ABT-751G) and sulfate (ABT-751S) conjugates. We performed a pharmacogenetic
investigation of ABT-751 pharmacokinetics using in-vitro data to guide the selection of genes for
genotyping in a phase I trial of ABT-751.
Methods—UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) enzymes were
screened for ABT-751 metabolite formation in vitro. Forty-seven cancer patients treated with
ABT-751 were genotyped for 21 variants in these genes.
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Results—UGT1A1, UGT1A4, UGT1A8, UGT2B7, and SULT1A1 were found to be involved in
the formation of inactive ABT-751 glucuronide (ABT-751G) and sulfate (ABT-751S). SULT1A1
copy number (> 2) was associated with an average 34% increase in ABT-751 clearance (P=
0.044), an 18% reduction in ABT-751 AUC (P = 0.045), and a 50% increase in sulfation
metabolic ratios (P=0.025). UGT1A8 rs6431558 was associated with a 28% increase in
glucuronidation metabolic ratios (P =0.022), and UGT1A4*2 was associated with a 65% decrease
in ABT-751 Ctrough (P = 0.009).
Conclusion—These results might represent the first example of a clinical pharmacokinetic effect
of the SULT1A1 copy number variant on the clearance of a SULT1A1 substrate. A-priori selection
of candidate genes guided by in-vitro metabolic screening enhanced our ability to identify genetic
determinants of interpatient pharmacokinetic variability.
Keywords
ABT-751; drug development; drug metabolism; pharmacogenetics; phase I; sulfotransferase;
UDP-glucuronosyltransferase
Introduction
The face of drug development is developing rapidly toward biomarker-based approaches for
enriching the population of responsive patients [1]. However, pharmacokinetics remain one
of the most important determinants of the target–drug interaction, and inadequate drug
concentration at the target might prevent drug activity. Most anticancer agents have wide
interindividual pharmacokinetic variability, and their systemic exposure after standard doses
can vary 2–10-fold among patients [2]. During drug development, the inability to predict the
variation in exposure might prevent the identification of safe and effective dosing of the
chemotherapy, leading to early termination of development programs.
The process by which new drugs are developed should be supported by the identification of
the genetic component of pharmacokinetic variation. After the identification of the main
elimination pathways from either animal disposition or mass balance studies in humans, we
hypothesize that an economical and efficient approach would be to use preclinical data on
drug disposition to inform a pharmacogenetic study. We applied this principle in a phase I
trial of ABT-751.
ABT-751 is a novel oral antitubulin agent that binds to the colchicine-binding site of β-
tubulin, a site distinct from that of other anticancer antimitotic drugs [3]. It has been
evaluated in adult and pediatric patients with advanced cancer in phase I clinical trials [4–7].
Pharmacological data from early clinical trials show that the glucuronide (ABT-751G) and
sulfate (ABT-751S) conjugates are two major and inactive metabolites of ABT-751 [8,9].
The area under the plasma concentration–time curves (AUCs) of the conjugated forms of
ABT-751 were two- to three-fold higher than that of the parent compound [8], indicating a
major role of phase II metabolism in ABT-751 clearance. Renal clearance of ABT-751 was
negligible compared with the total clearance, indicating that ABT-751 is primarily
eliminated through hepatic metabolism [8].
Human UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) enzymes belong
to two distinct superfamilies. Several human isoforms with overlapping specificities are
responsible for the metabolism of numerous drugs, environmental toxins, and endogenous
compounds [10]. Similar to many other substrates [11–13], germline genetic variation in
UGT and SULT may impact the interpatient variability in the disposition of ABT-751. In this
study, we demonstrate how to perform an optimized pharmacogenetic assessment of a novel
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anticancer agent during its early phase of development and to describe the pharmacogenetic
associations.
Methods
Patients, study design, and treatment plan
Human investigations were performed after review and approval by the Biological Sciences
Division/University of Chicago Hospitals Institutional Review Board and in accordance
with Federal Wise Assurance for the protection of human participants. Participants provided
written informed consent before being enrolled. Patients were eligible for the study if they
had a solid tumor or non-Hodgkin lymphoma refractory to standard therapy. Patient
characteristics are shown in Table 1. Details on the patient eligibility and evaluation, and
results on safety and efficacy are reported in Supplemental digital content 1 (http://
links.lww.com/FPC/A599). ABT-751 was administered orally once daily (QD) or twice
daily (BID) for 21 consecutive days, followed by a 7-day recovery period (28-day cycle).
The starting dose for the QD regimen was 25mg (flat dose), which was subsequently
escalated to 50mg, and then in 50 mg increments thereafter. After 25 mg QD was found to
be safe, the BID regimen was initiated in parallel with 25mg BID, with subsequent dose
escalations by 25 mg BID. Dose escalation proceeded separately for QD and BID regimens.
Three patients were initially enrolled at each dose level using a standard ‘3+3’ design [14].
If no patient experienced dose-limiting toxicity (DLT) during cycle 1, dose escalation
proceeded to the next level. Results of the dose escalation and DLTs are reported in
Supplemental digital content 2 (http://links.lww.com/FPC/A600).
Pharmacokinetics
Blood samples were collected on day 1 of the first administration at cycle 1 before dosing,
and at 0.5, 1, 2, 4, 6, and 8 h after dosing. A predose sample was also obtained at day 15.
Plasma concentrations of ABT-751, ABT-751G, and ABT-751S were measured using liquid
chromatography with tandem mass spectrometry as described previously [8].
Pharmacokinetic parameters for ABT-751 were estimated using noncompartmental methods
and included maximal concentration (Cmax), time to Cmax (Tmax), and the area under the
concentration–time curve from 0 to the last time point (AUC0–8). Metabolic AUC ratios of
metabolite over ABT-751 and clearance of ABT-751 (calculated as dose/AUC) were also
determined. On day 15, plasma predose concentration (Ctrough) of ABT-751 was measured.
In-vitro screening of recombinant UGTs and kinetic analyses
Microsomes from recombinant UGT1A1, 3, 4, 6, 7, 8, 9, 10, and UGT2B4, 7, 15, 17, as well
as negative control insect cell microsomes were obtained from BD Gentest (Woburn,
Massachusetts, USA). Human liver microsomes (HLMs) (n=15) were prepared using
differential centrifugation methods [15], with livers obtained with human participant
approval through the Liver Tissue Procurement and Distribution System funded by NIH
contract #N01-DK-9-2310. To screen for UGT activity, incubations were performed in
duplicate for 120 min as described previously for morphine [16] using 300 mg of protein
and 200 μmol/l ABT-751.
ABT-751G formation rates were measured at 277 nm by high-performance liquid
chromatography (HPLC) using a YMC AM-312 C18 column (5 μm, 150 mm × 6.0 mm) and
a YMC ODS-AM S-5 guard column (120 A, 4.0 × 20 mm; Waters Corp., Milford,
Massachusetts, USA). The mobile phase consisted of acetonitrile (A) and 0.05 mol/l
ammonium acetate (pH 5.5) (B) at 1.2 ml/min using the following gradient: 0–15 min 25%
A and 75% B, 15.1–20 min from 25% A and 75% B to 75% A and 25% B, and 20.1–30 min
75% A and 25% B. ABT-751G standards (range: 1–125 μmol/l) were processed as
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described above. 4-Methyl-N-(4-nitrophenyl) benzene-sulfonamide (1.4 mmol/l; Sigma-
Aldrich, St Louis, Missouri, USA) was used as an internal standard. Kinetic studies were
carried out in duplicate with ABT-751 (0.01 to 1 mmol/l) using the selected UGTs that
showed glucuronidation activity on the initial screen. Vmax was normalized by the relative
protein expression as described previously [17]. Apparent kinetic values were calculated
using SigmaPlot 9.0 (Systat Software Inc., Richmond, California, USA).
In-vitro screening of recombinant SULTs and kinetic analyses
cDNA sequences for human cytosolic SULT1A1*1, 1A1*2, 1A1*3, 1A2, 1A3/1A4, 1B1,
1C2, 1E1, 2A1, 2B1a, 2B1b, and 4A1 were used to transfect COS-1 cells [18]. SULT1A1*2
and *3 are variant isoforms of the SULT1A1*1 reference sequence isoform [19]. Cytosol
preparations obtained from the transfected cells were used as the source of recombinant
human SULT proteins using cells transfected with ‘empty’ vector as controls. Screening
experiments were conducted with SULT isoforms, 0.4 μmol/l [35S]-PAPS, and a range of
ABT-751 concentrations (0.0001–1 mmol/l), according to a previous study [20]. ABT-751
dissolved in DMSO served as the acceptor substrate. Kinetic experiments were conducted
with recombinant SULT isoforms that showed appreciable activity with ABT-751 (0.2–1
mmol/l). Apparent kinetic values were calculated according to Cleland [21].
Genotyping of UGT and SULT variants
DNA and pharmacokinetic information was available from 47 patients. Twenty-one variants
in the UGT1A1, UGT1A4, UGT1A8, UGT2B7, and SULT1A1 genes were selected for
genotyping (Table 2) according to our in-vitro screen for ABT-751 conjugation. UGT
genotyping methods and primers are listed in Supplemental digital content 1 (http://
links.lww.com/FPC/A599) and Supplemental digital content 3 (http://links.lww.com/FPC/
A601). Previously established genotyping methods were used for SULT1A1 single-
nucleotide polymorphisms (SNPs) [24] and copy number variation [11]. UGT and SULT
genotype frequencies and the analysis of Hardy–Weinberg equilibrium are described in
Supplemental digital content 4 (http://links.lww.com/FPC/A602).
Statistics and data analysis
The association between UGT and SULT variants and the pharmacokinetics of ABT-751
was assessed by linear regression. The primary analyses were carried out using the
pharmacokinetic parameters at day 1 in patients of all ethnicities (self-reported). The
pharmacokinetic parameters used in this analysis were the dose-normalized AUCs and Cmax
of ABT-751, ABT-751G, and ABT-751S, the AUC metabolite/parent ratios, and ABT-751
clearance. We also analyzed the association between gene variants and dose-normalized
ABT-751 Ctrough levels at day 15. To meet the assumption of a normal distribution of the
data in the linear regression, pharmacokinetic parameters were natural log-transformed. To
describe the magnitude of the SNP effect on ABT-751 pharmacokinetics, percent changes
were calculated from untransformed data. The genetic association was tested for three
models: recessive, dominant, and additive. For the associations that were significant in
univariate analysis, we also tested the robustness of these associations using clinical
demographics (which were significant in univariate analysis) as covariates in a multivariate
analysis. The clinical demographics were sex, height, weight, and age. A P value less than
0.05 (two sided) was used as a cutoff for statistical significance, not corrected for multiple
comparisons. Because of the small sample size and the number of comparisons, the P values
for the associations are nominal. Hardy–Weinberg equilibrium was also evaluated for all the
variants (P<0.01 for significance).
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Our approach started with screening 24 expression systems for human UGT and SULT
enzymes for ABT-751 conjugation. Of the 12 UGTs, UGT1A1, UGT1A4, UGT1A8, and
UGT2B7 could glucuronidate ABT-751 (Table 3). We compared the catalytic properties of
the human UGTs highly expressed in the human liver with those from pooled HLMs.
UGT1A1, UGT1A4, and UGT2B7 showed kinetics similar to those of HLMs. Expression
systems for common variant isoforms of SULT1A1 were also tested for ABT-751 sulfation.
Only SULT1A1*1, *2, *3, and SULT2b showed SULT activity against ABT-751.
SULT1A1*2 and *3 showed reduced Vmax and increased Km (in particular SULT1A1*2)
compared with SULT1A1*1, the reference sequence SULT1A1 enzyme. Despite showing
sulfation activity toward ABT-751, SULT2B1b showed a very low Vmax compared with
SULT1A1*1.
The screening of candidate isoforms led to the selection of the UGT1A1, UGT1A4,
UGT1A8, UGT2B7, and SULT1A1 genes for genotyping in cancer patients phenotyped for
ABT-751 pharmacokinetics. Of these five genes, variants were selected according to a
combination of different criteria, including their expected frequency in a European
population (alleles with a frequency of 0.10 or higher), evidence of functionality, and
haplotype tagging from available resequencing data. This approach led to the selection of 21
variants for genotyping.
Using both parent drug and metabolite pharmacokinetics, we tested the association between
selected gene variants and interpatient variability in ABT-751 disposition. SULT1A1 copy
number variation (>2 SULT1A1 gene copies) was associated with an average 18% reduction
in ABT-751 AUC (P=0.045, n=42), a 34% increase in ABT-751 clearance (P=0.044, n=42),
and a 50% increase in sulfation metabolic ratios (P=0.025, n=42; Fig. 1a–c). The number of
SULT1A1 copies (i.e. 2 vs. 3 vs. 4 vs. 5) was also associated with increased sulfation
metabolic ratios, showing a clear gene–dosage effect (P=0.027, n=42; Fig. 1d). UGT1A8
rs6431558 was associated with a 28% increase in glucuronidation metabolic ratios
(P=0.022, n=47; Fig. 2a). UGT1A4*2 was associated with a 65% reduction in Ctrough
(P=0.009, n=37; Fig. 2b). None of the clinical demographics had any effect on the
pharmacokinetic parameters described in the above associations in univariate analysis
(P>0.05, data not shown). They were not tested in multivariate analysis. None of the other
gene variants showed an association with ABT-751 pharmacokinetic parameters (P>0.05,
data not shown). Because of the small sample set, we did not test for a correlation between
SNPs and the presence of DLT. Patients with DLT had higher dose-normalized ABT-751
AUC (mean±SD=0.21±0.05 h/l, n=7) than patients who did not experience DLT (0.16±0.05,
n=40; P=0.03). At the dose intervals tested in this study, the pharmacokinetics of ABT-751
(Table 4) is linear, consistent with previous reports [8,25].
Discussion
The knowledge of the key determinants of drug disposition can facilitate the development of
biomarkers to individualize drug dosing. In particular, for first-in-human studies, a typical
preclinical in-vitro analysis for a new molecular entity may cover only CYP450s and p-
glycoprotein [26]. Only recently has the FDA provided guidance for including UGTs in the
panel of screened enzymes [27]. These screenings aim to identify the potential for drug–
drug interactions, rather than select candidate genes for genotyping in early studies.
However, when a drug is mainly eliminated by conjugation, such as ABT-751, a different
set of assays should be run to elucidate the specific metabolic isoforms likely to inactivate
the drug in question. Available prediction models based on structure similarity to known
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probes are not accurate enough to predict substrate specificity of the major enzymes of
metabolism. We have performed several enzyme screenings using expression systems and
liver fractions, allowing the identification of the candidate genes of drug disposition for
future investigation [16,17,28–31]. This prioritization significantly narrowed the number of
genes to be interrogated for common variation in patients receiving pharmacological
treatment, and has led to germline biomarkers of clinical use, such as the UGT1A1*28 allele
[22]. This model was applied successfully to ABT-751, a novel oral antitubulin agent.
One of the major factors responsible for interpatient variability in pharmacokinetics is the
presence of functional variants in genes of drug metabolism. For ABT-751, the main
elimination pathway is through glucuronidation and sulfation into inactive metabolites [8].
The UGT and SULT superfamilies combined comprise more than 25 human isoforms. In
this study, the in-vitro activity screens for ABT-751 conjugation led us to identify the major
genes responsible for ABT-751 conjugation. This approach restricted the genetic
investigation of associations with pharmacokinetics to only five candidate genes, instead of
interrogating all the 25 UGTs and SULTs, reducing incremental costs and limiting the
number of testable hypotheses.
Pharmacogenetic associations might be pharmacologically relevant when performed in a
setting of carefully selected genes, established SNP functionality, and detailed
pharmacokinetic assessment. For example, despite the small number of patients in our study
and potential confounding of dose escalation, SULT1A1 copy number variation was shown
to affect ABT-751 disposition. Increased copy numbers of SULT1A1 increased the clearance
of the parent drug through sulfation into inactive and more easily extracted sulfated
metabolites of ABT-751. By measuring the AUC of the ABT-751 sulfated metabolite, we
were able to confirm that this effect is mediated through sulfation, as the ABT-751 sulfation
ratios increased in parallel with the increase in the number of SULT1A1 copies (Fig. 1d).
The SULT1A1 gene–dosage effect on the ABT-751 metabolic ratios strikingly mirrors
previous observations on ex-vivo hepatic SULT1A1 activity made by investigators in our
group [11]. It should be kept in mind that the statistical significance of these findings has not
been corrected for multiple testing. However, the collected evidence from this paper might
represent the first example of a clinical pharmacokinetic effect of the SULT1A1 copy
number variant on the clearance of a SULT1A1 substrate. As SULT1A1 is the most highly
expressed hepatic SULT and is involved in the biotransformation of a wide variety of
endobiotics and xenobiotics [32], the assessment of SULT1A1 copy numbers should be
included to predict pharmacokinetic changes of SULT1A1 substrates that are eliminated
primarily through sulfation. Rational selection of genes and previously established evidence
of the molecular function of their variants (such as SULT1A1 copy number variation) might
still lead to relevant discoveries and validations, even in studies with limited statistical
power.
Our study provides evidence on the clinical pharmacokinetic relevance of the SULT1A1
copy number polymorphism in humans and generates novel hypotheses on the functionality
of UGT variants. For example, UGT1A8 rs6431558 is an intronic haplotype-tagging SNP
associated with glucuronidation ratios (Fig. 2a) but, so far, there is no supportive molecular
function. UGT1A8 has extrahepatic intestinal localization [33], and is unlikely to affect
systemic plasma disposition of ABT-751; accordingly, an effect of this SNP on the
disposition of the ABT-751 parent drug was not observed. Intestinal glucuronidation might
affect the oral bioavailability and enterohepatic cycling [34], and the putative role of
UGT1A8 variants in these processes should be evaluated.
Another association detected in this study is with UGT1A4*2, an amino acid changing
variant [35] with low frequency in the population. Although UGT1A4*2 was associated with
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ABT-751 Ctrough at day 15, there were only four heterozygous patients with reduced Ctrough
(Fig. 2b). This effect would be consistent with the increased activity conferred by this
variant for some substrates, including tobacco procarcinogens [35]. An increase in Ctrough
glucuronidation ratios in the four UGT1A4*2 heterozygous patients was detected (P=0.028,
data not shown). The hypothesis that UGT1A4*2 conferred increased ABT-751
glucuronidation leading to reduced Ctrough is intriguing, but remains to be confirmed.
Using ABT-751 disposition as our working model, this study shows the utility of performing
detailed preclinical and clinical assessments of the main pathways of metabolism in early
drug development. We have shown that the elucidation of candidate genes and
pharmacokinetic phenotyping of parent drug and metabolites can lead to the identification of
biomarkers for future testing. This rational strategy might overcome the intrinsic difficulty
of performing biomarker discovery in phase I, which is not an ideal setting for
pharmacogenetic investigations because of the limited sample sizes and patient
heterogeneity.
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SULT1A1 genetic association with ABT-751 pharmacokinetics. Association between 2 vs.
>2 SULT1A1 copy number and (a) ABT-751 AUC, (b) ABT-751 clearance, and (c) sulfation
metabolic ratios (ABT-751S AUC/ABT-751 AUC). Association of 2 vs. 3 vs. 4 vs. 5
SULT1A1 copy number and sulfation metabolic ratios (d). Natural log-transformed data are
shown. Horizontal lines represent the mean value of the log-transformed data.
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UGT1A4 and UGT1A8 genetic associations with ABT-751 pharmacokinetics. Associations
between (a) UGT1A8 rs6431558 and glucuronidation metabolic ratios (ABT-751G AUC/
ABT-751 AUC) and (b) UGT1A4*2 and ABT-751 Ctrough. Natural log-transformed data are
shown. Horizontal lines represent the mean value of the log-transformed data.
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Number of patients enrolled 73
 With pharmacokinetic data 66



























50% White Hispanic and 50% Native American.
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